Breaking News Instant updates and real-time market news.

DVA

DaVita

$63.16

-0.17 (-0.27%)

, HUM

Humana

$208.14

0.26 (0.13%)

13:51
11/28/16
11/28
13:51
11/28/16
13:51

Humana, JSA partner to add PCP to Medicare Advantage Plan network in Florida

JSA Medical Group, a DaVita Medical Group (DVA), and Humana (HUM) have teamed up to add one primary care practice to Humana's Medicare Advantage Plan network in Florida. Humana is adding this new primary care practice location to its network in an effort to improve access to high quality care and helping to increase patients' ability to manage their own care which may improve their health and well-being. The new practice operated by JSA Medical Group accepts certain Medicare Advantage plans administered by Humana and does not accept Medicare Advantage plans administered by other carriers. The new practice will also accept traditional Medicare.

DVA

DaVita

$63.16

-0.17 (-0.27%)

HUM

Humana

$208.14

0.26 (0.13%)

  • 06

    Dec

  • 07

    Dec

DVA DaVita
$63.16

-0.17 (-0.27%)

09/20/16
RAJA
09/20/16
UPGRADE
Target $75
RAJA
Outperform
DaVita upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst John Ransom upgraded DaVita to Outperform and established a $75 price target. saying shares have corrected by approximately 18% following Q2 results and concerns about ACA exchange exposure. The analyst views valuation as attractive and thinks ACA exposure is a bit less than previous estimates. Further, investor expectations for DVA Medical Group are low and represent less than 10% EBIT, Ransom wrote.
10/13/16
RHCO
10/13/16
NO CHANGE
RHCO
Price targets cut on dialysis stocks at SunTrust
SunTrust analyst David MacDonald lowered his price targets on dialysis stocks, citing CMS' recent request for information and resulting payor risk and lower assumed multiples. The analyst cut his price target on American Renal Associates (ARA) to $24 from $34, on DaVita (DVA) to $66 from $80 and on Fresenius Medical (FMS) to $48 from $54. He maintains Buy ratings on American Renal and Fresenius but said he does not expect the stocks to rise significantly until the CMS matter is resolved. MacDonald keeps a Hold rating on DaVita.
10/31/16
BARD
10/31/16
NO CHANGE
Target $68
BARD
Outperform
Baird views news from DaVita as 'de-risking event'
Baird analyst Whit Mayo views today's announcement from DaVita as a "de-risking event" with higher than expected patient numbers. The disclosed $230M worst-case operating income hit includes on-exchange and off-exchange patients, and is in the range of what was expected, Mayo tells investors in a research note. DaVita earlier today announced that it will suspend support for applications to the American Kidney Fund for charitable premium assistance by Medicaid patients who are seeking additional coverage through an Affordable Care Act plan. The change will affect approximately 2,000 patients, the company said. To reflect a "scenario for payer mix reversion," Mayo lowered his 2017 earnings per share estimate for DaVita to $4.06 from $4.69. He also cut his price target for the shares to $68 from $85. Mayo keeps an Outperform rating on DaVita, which is trading up 5% to $57.92.
11/01/16
BARD
11/01/16
NO CHANGE
Target $68
BARD
Outperform
DaVita price target lowered to $68 from $85 at Baird
Baird analyst Whit Mayo lowered his price target on DaVita to $68 from $85 following the company's better than feared announcement of its potential $230M hit from on-exchange and off-exchange patients related to a potential CMS ruling regarding charitable premium assistance for ESRD patients. The analyst cut his estimates, although he feels the announcement de-risks the stock. Mayo maintained his Outperform rating on DaVita shares.
HUM Humana
$208.14

0.26 (0.13%)

11/11/16
FBCO
11/11/16
UPGRADE
Target $210
FBCO
Outperform
Humana upgraded to Outperform on Medicare Advantage earnings at Credit Suisse
As previously reported, Credit Suisse upgraded Humana to Outperform from Neutral and raised its price target to $210 from $175. Analyst Scott Fidel said Trump's victory and the Republic sweep will be favorable for Medicare Advantage, adding to Humana's earnings.
11/11/16
11/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Equal Weight from Underweight at Barclays with analyst Kannan Venkateshwar saying ESPN is "de-risked" going into 2017 after management quantified the impact of the new NBA contract. 2. Aetna (AET) and Humana (HUM) were upgraded to Outperform from Neutral at Credit Suisse, while the firm upgraded WellCare (WCG) to Neutral from Underperform. 3. Anadarko (APC) and EOG Resources (EOG) were upgraded to Buy from Neutral at Guggenheim. 4. Tiffany (TIF) upgraded to Outperform from Market Perform at Cowen with analyst Oliver Chen saying he believes the luxury market is coming back and Tiffany is well positioned and a trusted brand. 5. Vornado (VNO) upgraded to Buy from Neutral at BofA/Merrill with analyst James Feldman saying he believes the decision to spin DC and partner with JBG will allow management to focus on the New York City platform and notes the Penn Plaza corridor is rapidly improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
JEFF
11/15/16
NO CHANGE
Target $230
JEFF
Buy
Humana price target raised to $230 from $206 at Jefferies
Jefferies analyst David Windley raised his price target for Humana to $230 after meeting with CFO Brian Kane. The potential to double Medicare Advantage enrollment under a Paul Ryan-type plan "introduces a significant upside scenario," Windley tells investors in a research note. The analyst keeps a Buy rating on the shares.
11/21/16
WELS
11/21/16
NO CHANGE
WELS
Humana is best positioned health insurer, says Wells Fargo
Wells Fargo believes that Humana (HUM) is the best positioned health insurer going forward, given Wells' estimate that it obtains 70%+ of its revenue from Medicare Advantage. The firm expects the latter program to be strengthened under the Trump Administration. Wells keeps an Outperform rating on Humana, which has agreed to be acquired by Aetna (AET).

TODAY'S FREE FLY STORIES

ROST

Ross Stores

$57.78

1.25 (2.21%)

06:42
06/29/17
06/29
06:42
06/29/17
06:42
Technical Analysis
Technical View: Ross Stores gives back prior day gains in pre-market »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCMLY

LafargeHolcim

$11.78

0.115 (0.99%)

06:42
06/29/17
06/29
06:42
06/29/17
06:42
Downgrade
LafargeHolcim rating change  »

LafargeHolcim downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$17.15

0.5 (3.00%)

06:40
06/29/17
06/29
06:40
06/29/17
06:40
Technical Analysis
Technical View: Valeant moves higher in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

, BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

06:38
06/29/17
06/29
06:38
06/29/17
06:38
Hot Stocks
Home Capital gets TSX approval for equity investment by Berkshire Hathaway »

Home Capital Group is…

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRO

Monro Muffler

$41.70

-3.45 (-7.64%)

06:36
06/29/17
06/29
06:36
06/29/17
06:36
Downgrade
Monro Muffler rating change  »

Monro Muffler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFS

CHF Solutions

$0.62

-0.0074 (-1.17%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Initiation
CHF Solutions initiated  »

CHF Solutions initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$98.95

0.42 (0.43%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Earnings
McCormick backs FY17 adj. EPS view of $4.05-$4.13 »

Sees FY17 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

MKC

McCormick

$98.95

0.42 (0.43%)

06:31
06/29/17
06/29
06:31
06/29/17
06:31
Earnings
McCormick reports Q2 adj. EPS 82c, consensus 76c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

06:25
06/29/17
06/29
06:25
06/29/17
06:25
Recommendations
Pier 1 Imports analyst commentary  »

Pier 1 Imports shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

06:22
06/29/17
06/29
06:22
06/29/17
06:22
Recommendations
Weibo analyst commentary  »

Weibo content block to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

, SINA

SINA

$86.75

1.78 (2.09%)

06:18
06/29/17
06/29
06:18
06/29/17
06:18
Periodicals
China's Weibo to block unlicensed video conternt, Reuters reports »

China's Weibo (WB)…

WB

Weibo

$69.36

0.28 (0.41%)

SINA

SINA

$86.75

1.78 (2.09%)

FENG

Phoenix New Media

$2.70

-0.04 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$27.83

-0.35 (-1.24%)

06:13
06/29/17
06/29
06:13
06/29/17
06:13
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$37.89

0.65 (1.75%)

06:10
06/29/17
06/29
06:10
06/29/17
06:10
Recommendations
Allison Transmission analyst commentary  »

Piper 'growing more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$27.69

1.13 (4.25%)

06:05
06/29/17
06/29
06:05
06/29/17
06:05
Hot Stocks
Noah Holdings authorizes $50M share repurchase program »

Noah Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Earnings
Greenbrier sees FY17 EPS $3.45-$3.65, consensus $3.49 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

PDS

Precision Drilling

$3.36

0.03 (0.90%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Downgrade
Precision Drilling rating change  »

Precision Drilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:03
06/29/17
06/29
06:03
06/29/17
06:03
Earnings
Greenbrier reports Q3 EPS $1.03, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

SPX

S&P 500

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.00

0.46 (7.03%)

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Recommendations
ImmunoGen analyst commentary  »

ImmunoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.43

0.17 (0.76%)

05:58
06/29/17
06/29
05:58
06/29/17
05:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.90

0.09 (0.08%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.99

0.49 (1.56%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$19.69

0.8 (4.24%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$29.70

-0.63 (-2.08%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.67

-2.77 (-4.37%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.